VolitionRX Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Conference call to take place on tuesday may 14 at 8:30 a.m. u.s eastern time henderson, nev.

Henderson, nev. , april 23, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has announced that its nu.q® vet cancer test is now available in-clinic to veterinarians across the u.s and europe through antech, a leading veterinary diagnostics company.

Conference call to discuss financial and operational results scheduled for tuesday, march 26 at 8:30 a.m. u.s. eastern time henderson, nev.

Conference call to take place on tuesday march 26 at 8:30 a.m. u.s eastern time henderson, nev.

Henderson, nev. , march 20, 2024 /prnewswire/ -- volitionrx limited (nyse american: vnrx) ("volition"), a multi-national epigenetics company, has agreed a supply agreement with fujifilm vet systems co. ltd ("fujifilm vet systems"), a leading veterinary diagnostic laboratory service, to launch the nu.q® vet cancer test to veterinarians in japan.

The International Monetary Fund believes that most of the impact from tighter money policies has already affected the U.S. economy, with the rest expected this year. Despite worries about a recession, the U.S. has shown resilience and strong growth since interest rates started going up in March 2022.

VolitionRx (NYSE-A:VNRX) has outlined its plans to advance its veterinary diagnostics platform after a successful 2023. Among the notable achievements in the past year, Volition successfully launched the Nu.Q Vet Cancer Test in significant markets through various licensing, supply, and distribution agreements.

VolitionRx (NYSE-A:VNRX) told investors it has secured €5 million (roughly $5.5 million) in financing from Belgium's Wallonie Entreprendre (WE) for the ongoing development of its Nu.Q product portfolio. The multi-national epigenetics company said the funds will also be used to advance the clinical and regulatory program for Nu.Q NETs, which it believes will aid the early diagnosis of diseases such as sepsis, as it works with leading clinicians and researchers to help facilitate the effective introduction of the diagnostic solution into clinical practice.

VolitionRx Limited (NYSE:VNRX ) Q3 2023 Earnings Conference Call November 15, 2023 8:30 AM ET Company Participants Scott Powell - Executive Vice President, Investor Relations Cameron Reynolds - President and Group Chief Executive Officer Terig Hughes - Group Chief Financial Officer Tom Butera - Chief Executive Officer, Volition Veterinary Subsidiary Andrew Retter - Medical Consultant, Volition Louise Batchelor - Chief Marketing and Communications Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald Bruce Jackson - The Benchmark Company Tim Moore - EF Operator Good morning, ladies and gentlemen. Thank you for standing by.

VolitionRx (NYSE-A:VNRX) said its Nu.Q Vet Cancer Test revenue has seen a nearly five-fold increase in sales over the first nine months of 2023 compared to the same period last year. The Nu.Q test involves analyzing nucleosomes, which are structural units of DNA, to identify specific patterns or changes associated with the presence of cancer in animals.

Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.

VolitionRx (NYSE-A:VNRX) told investors it has joined forces with Veterinary Pathology Group (VPG) to launch the Nu.Q Vet Cancer Test to veterinary practices in the UK and Ireland. The NuQ Vet Cancer Test is a groundbreaking tool for the early detection and monitoring of cancer in dogs and VPG will be the first-to-market diagnostics laboratory in the UK to offer the test, the company said.

VolitionRx (NYSE-A:VNRX) has highlighted a recently published paper in Annals of Intensive Care which shows the company's Nu.Q NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and it could play a vital role in sepsis prognosis. The paper is about a 150-patient study led by Professor Guillaume Monneret, Head of Clinical Immunology Laboratory at Hospices Civils de Lyon in France.

VolitionRx (NYSE-A:VNRX), the multinational epigenetics company, said it was “delighted” to host Ambassador Michael Adler, the US Ambassador to the Kingdom of Belgium, for an exclusive tour of its state-of-the-art research, development, and manufacturing facilities located in Isnes, Belgium. "Ambassador Adler's visit today was an ideal opportunity for us to celebrate this collaborative work and highlight the close ties we have fostered between US and Belgian stakeholders over the last 13 years,” Gaetan Michel, Volition's COO said in a statement.

VolitionRx (NYSE-A:VNRX) said it will be presenting three scientific abstracts about cancer detection tools at the annual congress of the European Society for Medical Oncology (ESMO) 2023. "We are delighted to be attending ESMO 2023 and have the opportunity to share exciting new data in lung cancer and glioblastoma and introduce what we believe to be an entirely new method for the detection of cancer,” Volition's chief scientific officer Dr. Jake Micallef said in a statement.